Answers are grounded in this paper and cite their sources.
Longevity medicine seeks to extend both lifespan and healthspan, the years in which people can climb stairs, recover from illness, and live independently.Respiratory function and aerobic capacity contribute to these goals through different components of oxygen transport, yet their prognostic associations are often conflated with evidence that improving a measurement reverses aging.In this narrative review, we examine respiratory and aerobic reserve as complementary therapeutic targets, integrating pulmonary physiology, human aging biology, and intervention studies.We define reserve as the margin between a person's capacity and the demands of a given activity, not as another biological age score.Aging can narrow that margin at any step of oxygen transport, from ventilatory mechanics and the alveolar epithelium to the pulmonary microvasculature, cardiac delivery, and skeletal muscle mitochondria.Because these steps need not decline together and one can partly compensate for another, normal spirometry can coexist with poor fitness, whereas impaired lungs can coexist with preserved exercise performance.The strongest evidence still belongs to established interventions, such as aerobic and resistance training, pulmonary rehabilitation, smoking cessation, and selected disease-specific treatments, which have been shown to preserve function, reduce disability, or improve survival in defined populations, often without normalizing lung function.Emerging senolytics, nicotinamide adenine dinucleotide precursors, mitophagy interventions, metformin, mechanistic target of rapamycin inhibitors, and photobiomodulation have mostly been tested in small, short human trials with variable evidence.Recent trials also challenge the assumption that gerotherapeutics necessarily enhance exercise adaptation: in older adults, metformin blunted the mitochondrial response to aerobic training, and weekly sirolimus did not augment training gains.We therefore treat molecular target engagement, physiological improvement, daily function, clinical healthspan outcomes, and lifespan as separate links in the chain of evidence, and we emphasize indication-specific benefit versus harm.Three questions should guide future research: whether the hidden physiological cost of compensating for lung impairment predicts outcomes independently of preserved peak oxygen uptake, whether treating one limitation unmasks another, and whether gerotherapeutic-exercise combinations improve function beyond exercise alone.Integrating pulmonary assessment with directly measured exercise capacity and patientcentered outcomes offers a genuine strategy for evaluating longevity interventions while avoiding unsupported claims of lung rejuvenation.
No takes yet. Share an insight, caveat, or question.
Charokopos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: